AirOmatix, Inc. utilizes a patent-pending process to produce higher purity oxygen at four times the flow rate of traditional pressure swing adsorption (PSA) systems. Their portable oxygen concentrators provide patients with up to 6 L/min of oxygen flow, addressing the limitations of existing devices that only deliver up to 1.5 L/min.
Funding
$50K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current portable oxygen concentrators often struggle to provide sufficient oxygen flow rates for patients with high oxygen demands, limiting their mobility and quality of life. Traditional pressure swing adsorption (PSA) systems, commonly used in these devices, have inherent limitations in oxygen purity and flow rate.
Solution
AirOmatix addresses the limitations of existing portable oxygen concentrators by utilizing a novel, patent-pending process that produces higher purity oxygen at significantly increased flow rates. This technology enables the delivery of up to 6 liters per minute (L/min) of oxygen, a fourfold increase compared to traditional PSA systems. By providing higher oxygen flow, AirOmatix empowers patients with greater mobility and improved respiratory support, enhancing their overall well-being.
Target Audience
The primary target audience includes patients with respiratory conditions requiring supplemental oxygen, particularly those with high oxygen flow rate needs, as well as healthcare providers and home healthcare companies.
Features
- Patent-pending oxygen production process for enhanced purity and flow rate
- Portable oxygen concentrators delivering up to 6 L/min of oxygen
- Compact and lightweight design for increased patient mobility